Novo Nordisk has launched its anti-obesity drug Wegovy in India, which has become a key market for the company. Having already added 2,000 jobs, it is now expanding further with a focus on AI, ...

As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for the GLP-1 (glucagon-like ...

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Ozempic (semaglutide) and other GLP-1 medications have helped many people lose weight and manage chronic conditions like type ...

IcoSema was associated with significantly improved body weight and glycemic control among patients with inadequately controlled type 2 diabetes.

These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...

Powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs are helping to win the war against obesity in ...

Novo Nordisk (NYSE: NVO) and Regeneron Pharmaceuticals (NASDAQ: REGN), two leading drugmakers, have underperformed for most ...

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...